Graco Launches Disinfectant Sprayer Lineup

Graco Inc. has introduced the new line of SaniSpray HPTM airless sprayers. SaniSpray HP sprayers are uniquely built with high-grade materials that are compatible with List-N disinfectants – the specific types of disinfectants that meet the United States Environmental...

VA Selects Philips to Create World’s Largest Tele-Critical Care System

Royal Philips has announced that the U.S. Department of Veterans Affairs (VA) has awarded a contract to Philips to expand VA’s tele-critical care program, creating the world’s largest system to provide veterans remote access to intensive care expertise, regardless of...

BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation

BD (Becton, Dickinson and Company) has announced the availability of BD PurPrep patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83%...

PDI Receives Promising Testing Results of Super Sani-Cloth Wipes Against SARS-COV-2

PDI has generated data showing its Super Sani-Cloth wipes are effective against SARS-CoV-2, the virus that causes COVID-19. This is one of several of the company's hospital-grade disinfecting products being tested for efficacy against SARS-CoV-2 for submission to the...

Tru-D SmartUVC validated by randomized clinical trial on UV disinfection

Tru-D SmartUVC validated by randomized clinical trial on UV disinfection


The pioneer in no-touch UV disinfection has now been validated by a CDC-funded randomized clinical trial. Tru-D SmartUVC, short for “total room ultraviolet disinfection,” was the device of choice for the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study which was recently published in The Lancet. The BETR-D study proves that Tru-D can cut transmission of four major superbugs by a cumulative 30 percent.

“Since Tru-D came to market in 2007, we have been committed to innovation and the science behind our product,” said Chuck Dunn, CEO and President of Tru-D SmartUVC. “The BETR-D study further validates the effectiveness of our product and its capability to reduce the risk of acquisition of infections in health care settings.”

The BETR-D study was designed to examine the impact of enhanced terminal room disinfection as a method to prevent hospital-acquired infections (HAIs). The most comprehensive study on UV disinfection to date, the BETR-D study was a cluster randomized, multicenter crossover study with 2×2 factorial design to evaluate the impact of enhanced terminal room disinfection on acquisition and infection caused by multidrug-resistant organisms (MDROs).

“Our study is the first randomized trial to demonstrate that enhanced disinfection in the hospital can improve patient safety,” said Dr. Deverick Anderson, lead investigator of the BETR-D study.

The two-year, $2 million study led by principal investigator Dr. Daniel J. Sexton and lead investigator Dr. Deverick Anderson at Duke University School of Medicine and Duke Infection Control Outreach Network (DICON), collected data across nine hospitals and nearly 22,000 disinfection cycles for more than 120,000 patient days. Results proved that enhanced terminal room disinfection strategies reduced the cumulative incidence of MDROs, and the largest decreases were seen when Tru-D was added to the standard cleaning protocols.

Tru-D was the only UV disinfection device chosen for the study due to its patented Sensor360 technology that reduces the chance of human error in the disinfection process. The “brain” behind Tru-D, Sensor360 compensates for room variables such as size, shape, and contents to calculate and deliver the precise, lethal dose of UVC needed to disinfect a room. Operating from a single position in the room and administering a single cycle of UVC, Tru-D removes the guesswork from UV disinfection.

The study was sponsored by the CDC Prevention Epicenters Program (U54CK000164), the National Institute of Allergy and Infectious Diseases (K23AI095357) and the National Center for Advancing Translational Sciences (UL1TR001111).

For more information, visit



Submit a Comment

Your email address will not be published. Required fields are marked *